Merck’s “VIGORous” Defense Of Vioxx; Novartis, Wyeth Studies Might Help

Merck still believes that the initial cardiovascular safety signal seen for Vioxx can be explained by a cardioprotective effect from naproxen, the company said during an Oct. 13 press conference in New York City